[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Children's Hospital Los Angeles\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":662},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,43,0,25,[9,46,72,95,123,150,184,209,243,267,292,320,347,372,396,418,443,468,487,512,534,562,581,606,635],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100638320","patient-navigation-for-improving-transition-success-among-multiply-disadvantaged-young-adult-survivors-of-childhood-cancer-100638320",false,"NCT07630831","Patient Navigation for Improving Transition Success Among Multiply Disadvantaged Young Adult Survivors of Childhood Cancer","Inclusion Criteria:\n\n* diagnosed between the ages of 0-19 years with cancer or with any condition treated with cancer-like therapy.\n* currently in follow up at survivorship clinic or had a survivorship launch visit during the 12 months prior to study activation.\n* current age 20-29 (\\>95% of patients will be age 20-21)\n* meet LIFE Clinic transition readiness criteria, as clinically applied:\n* at least 5 years off treatment\n* medically stable\n* demonstrate a workable understanding of transition\n* have an identified primary care provider\n* able to speak and read English or Spanish\n* can provide informed consent.\n\nExclusion Criteria:\n\n* do not meet transition criteria\n* speak a language other than English or Spanish\n* are significantly impaired and cannot provide informed consent.","ALL","20 Years","29 Years",{"count":20,"type":21},190,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to improve the successful healthcare transition from pediatric to adult-focused care for childhood cancer survivors. The main questions it aims to answer are\n\n* Receipt of the intervention (vs. standard of care control) will increase the proportion of CCS achieving transition success to adult-focused survivorship care from 50% to 70%.\n* Receipt of the intervention (vs. standard of care control) will significantly reduce patients' unmet HRSN.\n* Intervention effectiveness will be moderated by sociodemographic factors (gender, race\u002Fethnicity, insurance status), medical risk for late effects, HRSN burden, and patient-reported outcomes (quality of life, self-efficacy).\n\nResearchers will compare those that receive intervention versus standard of care.\n\nPatients are randomized to either an intervention group, receiving structured PN-led sessions and tailored support for care transitions, or a control group receiving standard follow-up by a nurse case manager. High-HRSN patients in the intervention arm get monthly check-ins and coordinated handoffs to adult care providers for continuity.",[27],"Cancer Childhood",[29,30,31,32],"Childhood Cancer","Transition of care","Health-related social needs","Patient Navigation","NOT_YET_RECRUITING","2026-06-02",{"date":36,"type":37},"2026-06-05","ACTUAL",{"date":39,"type":21},"2026-07-01",{"date":41,"type":21},"2030-09-01",{"name":43,"class":44},"Children's Hospital Los Angeles","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100456075","phase-2-the-use-of-butyrate-therapy-in-pediatric-ulcerative-colitis-100456075","NCT05218850","The Use of Butyrate Therapy in Pediatric Ulcerative Colitis","Butyrate Therapy in Hispanic Children With Ulcerative Colitis","Inclusion Criteria:\n\n* 7-21 years, mild to moderate ulcerative colitis\n\nExclusion Criteria:\n\n* UC therapy within 4 weeks of study medication initiation\n* infectious colitis, -pregnancy","7 Years","21 Years",{"count":56,"type":21},10,[58],"PHASE2","Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis. This is a feasibility study to determine the efficacy of butryate enemas in pediatric ulcerative colitis.",[61],"Ulcerative Colitis",[63],"ulcerative colitis","RECRUITING",{"date":66,"type":37},"2026-06-04",{"date":68,"type":37},"2022-06-29",{"date":70,"type":21},"2027-06-30",{"name":43,"class":44},{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":45},"100172432","life-cancer-survivorship-database-for-pediatric-cancer-100172432","NCT01518400","LIFE Cancer Survivorship Database for Pediatric Cancer","A Research Database for Survivors of Childhood Cancer","Inclusion Criteria:\n\n* Been diagnosed with cancer or similar disease\n* Been diagnosed with cancer at 21 years of age or younger\n* Be currently off treatment and disease free",{"count":80,"type":21},5000,"OBSERVATIONAL","The purpose of this study is to develop a mechanism for utilizing the comprehensive clinical database of childhood cancer survivors at Childrens Hospital Los Angeles (CHLA) for research purposes. Using clinical information obtained from follow-up visits of childhood cancer survivors, the database will focus on interventions to improve health status and health-related quality of life in childhood cancer survivors. This study allows for establishment and analyses of a research database for LIFE survivors by the investigators listed herein. Over the last three decades, there has been marked improvement in survival following childhood cancer, with 5-year survival rates now approaching 80%. However, the use of cancer therapy at an early age can result in complications that may not be apparent until years later as the child matures. These resulting complications, called late effects, are principally related to the specific therapy employed and the age of the child at the time the therapy was administered. Late effects may affect virtually every body system and substantially impair quality of life. As many as two-thirds of childhood cancer survivors develop at least one late effect as a result of treatment, and approximately one-third have a late effect classified as severe or life threatening.",[84],"Pediatric Cancer",[84,86,87,88],"Cancer Late Effects","Cancer Survivor","Cancer Survivorship",{"date":66,"type":37},{"date":91,"type":4},"2009-02",{"date":93,"type":21},"2050-12",{"name":43,"class":44},{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":16,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100609386","comparing-two-school-based-sleep-health-interventions-to-promote-sleep-quality-in-youth-100609386","NCT07213908","Comparing Two School-Based Sleep Health Interventions To Promote Sleep Quality in Youth","Inclusion Criteria:\n\n* Age 12-18 years old\n* Sleep health problem (i.e. insomnia, evening circadian preference, short sleep duration, poor sleep quality)\n* Able to participate in a general education classroom.\n\nExclusion Criteria:\n\n* Previous participation in the study;\n* Symptoms or illness that precludes informed consent or engagement in study procedures ; youth not fluent in English, parent not fluent in English, or Spanish.",true,"12 Years","18 Years",{"count":105,"type":21},1320,[24],"The goal of this clinical trial is to conduct a comparative effectiveness trial that will evaluate two school-based interventions to improve adolescent sleep health: the standard Sleep Health Education (SHE) and a stepped care version of the Transdiagnostic Sleep and Circadian intervention (TS-C-STEP). The main questions it aims to answer \\[is\u002Fare\\]:\n\n* TS-C-STEP will yield superior outcomes relative to SHE at post-treatment and up to 12 months following treatment.\n* In this large and diverse sample, vulnerable subgroups (e.g. socioeconomically disadvantaged, racial, ethnic, rural, and youth with comorbid learning and\u002For mental health conditions) will experience greater benefits from TS-C-STEP compared to SHE on primary and secondary outcomes.\n\nResearchers will compare sleep quality to determine which intervention is most effective.",[109],"Sleep",[111,109,112,113],"Adolescents","Schools","Cognitive Behavioral Sleep Intervention","2026-05-21",{"date":116,"type":37},"2026-05-26",{"date":118,"type":37},"2026-03-31",{"date":120,"type":21},"2030-06-01",{"name":43,"class":44},2,{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":16,"minAge":131,"maxAge":17,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":45},"100599412","final-prototype-refinement-of-adaptive-cell-phone-support-100599412","NCT07084155","Final Prototype Refinement of Adaptive Cell Phone Support","Adaptive Cell Phone Support to Promote Medication Adherence Among Adolescents and Young Adults With Chronic Health Conditions","ACPS","Inclusion Criteria:\n\n* Children's Hospital Los Angeles patient\n* between 15-20 years old at enrollment\n* taking at least one oral medication per day for a chronic health condition\n* English speaking\n* demonstrating sufficient cognitive capacity to engage in the assent\u002Fconsent process and study procedures\n\nThere is no exclusion criteria.","15 Years",{"count":133,"type":21},35,[24],"The goal of this feasibility pilot trial is to finalize the design of a mobile health intervention for promoting medication adherence in a population of adolescents and young adults with chronic health conditions. The main question\\[s\\] it aims to answer are:\n\n1. Is the final version of the intervention sufficiently feasible, usable, and acceptable for evaluation in a randomized clinical trial?\n2. Do participants show improvements in medication adherence during their field testing of the intervention?",[137],"Medication Adherence",[139,140,141],"adolescents","mobile health","adherence","2026-05-08",{"date":144,"type":37},"2026-05-12",{"date":146,"type":37},"2026-03-25",{"date":148,"type":21},"2027-01-31",{"name":43,"class":44},{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":16,"minAge":102,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":168,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":45},"100580843","health-care-transition-readiness-short-form-video-intervention-100580843","NCT06842576","Health Care Transition Readiness Short-Form Video Intervention","Transition Readiness Mobile Health Intervention: Co-Design and Pilot Study","Inclusion Criteria:\n\n* Patients in subspecialty clinics\n* Between 12 and 17 years old\n* With access to an internet-connected device\n* Speaking English or Spanish\n* With sufficient cognitive capacity to understand the study procedures, as assessed via a teach back method.\n\nExclusion Criteria:\n\n* none","17 Years",{"count":159,"type":21},44,[24],"The goal of this clinical trial is to assess whether social-media style short-form health education videos can increase health care transition readiness, self-efficacy, emotional well-being, health literacy, and appointment attendance, compared with publicly available health education resources in adolescents with chronic illnesses. The main question it aims to answer is:\n\n-Hypothesize social media intervention will increase health care transition readiness, self-efficacy, emotional well-being, health literacy, and appointment attendance compared to publicly available health education website immediately post intervention and at 6 month follow up.\n\nParticipants will be randomly assigned to one of the interventions and access the intervention for 20 minutes and complete 30-60 minutes of surveys.",[163,164,165,166,167],"Health Care Transition Readiness","Health Literacy","Self Efficacy","Emotional Wellbeing","Appointment Attendance",[140,169,170,171,172,173,174,175,176,177],"health education","transition readiness","chronic illness","adolescence","health literacy","social media","video","self efficacy","emotional wellbeing",{"date":144,"type":37},{"date":180,"type":37},"2025-06-01",{"date":182,"type":21},"2026-06-30",{"name":43,"class":44},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":16,"minAge":102,"maxAge":103,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":198,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":45},"100526831","better-sleep-study-100526831","NCT06139861","Better Sleep Study","A Confirmatory Efficacy Trial of Engaging a Novel Sleep\u002FCircadian Rhythm Target as Treatment for Depression in Adolescents","Inclusion Criteria:\n\nExclusion Criteria:\n\n* mental health\u002Fbehavioral symptoms that would preclude productive engagement in study assessments or intervention (e.g., active psychosis; Bipolar Disorder; drug dependence\n* severe or unstable medical or psychiatric condition such that treatment has changed within the last month or is expected to change during the course of the study or that would preclude ability to adhere to study procedures (e.g. terminal end-stage cancer)\n* current use of medications or herbs with known effects on sleep\n* plan to undergo or have had medication change in the last 8 weeks",{"count":192,"type":21},200,[24],"The overall aim of this proposal is a confirmatory efficacy trial sufficiently powered and designed to test the hypothesis that improving the relationship between biological circadian timing and waketime, a novel modifiable target, improves depression outcomes in a subgroup of adolescents with depression and a misaligned relationship between biological circadian timing and waketime utilizing a cognitive-behavioral sleep intervention.",[196,197],"Depression in Adolescence","Delayed Sleep Phase",[199,111,109,200],"Depression","Intervention","2026-05-07",{"date":203,"type":37},"2026-05-11",{"date":205,"type":37},"2024-03-15",{"date":207,"type":21},"2028-08-01",{"name":43,"class":44},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":16,"minAge":217,"maxAge":54,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":222,"conditions":223,"keywords":228,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":45},"100491917","phase-1-acceptance-and-commitment-therapy-for-adolescents-and-young-adults-with-sickle-cell-disease-100491917","NCT05685368","Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease","Using Acceptance and Commitment Therapy (ACT) to Promote Mental Health and Transition Readiness in Youth With Sickle Cell Disease: A Community-Based Participatory Action Research (CBPAR) Approach","ACT for SCD","Youth Participant Inclusion and Exclusion Criteria The inclusion criteria for study participation are Be an adolescent and\u002For young adult (age 14-21) who has Sickle Cell Disease Willing to enroll in the ACT group jointly provided by the Division of Adolescent and Young Adult Medicine\u002FDepartment of Hematology and Oncology Participants can be active, waitlisted, or new patients at CHLA Participants must be able to understand and speak English, as the therapy will only be delivered in English Participants must have an English-speaking parent\u002Fguardian Able to provide consent\u002Fassent An adolescent or young adult that is pregnant is eligible to participate if consent can be obtained Participants must be developmentally typical Have a stable internet connection (via computer, tablet, or phone) with access to a webcam and a private space to engage in a group therapy sessions; Must consent to audio and video recording of initial interview. Must agree to attend 6 weekly ACT group session Youth participants will be asked to become a member of the CAB. To become a CAB member, the youth participant must consent\u002Fassent to participation in the ACT intervention. If a CAB member, they must be willing to engage in CAB interviews and meetings.\n\nThe exclusion criteria are:\n\nPrisoners or youth in detention centers Unable to understand or speak English Does not have SCD Clients who are at significant risk for suicide and self-injury will be excluded due to the intense levels of support required to support these individuals which would interfere with study procedures.\n\nAdolescents with families that require frequent intervention from the Department of Children and Family Services, are currently experiencing psychosis, or have severe health concerns that will impact study participation or attendance will be excluded.","14 Years",{"count":219,"type":21},66,[221,58],"PHASE1","The current study seeks to build on previous research that demonstrates the efficacy of Acceptance and Commitment Therapy in combating stigma by investigating the feasibility and acceptability of a protocol to support Black adolescents and young adults in coping with race related stress. The study will consist of a small, purposeful, non-randomized sample (N = 30) of clients enrolled into a 10-session Acceptance and Commitment Therapy group. The group will be offered as part of regular clinical care at the Division of Adolescent and Young Adult Medicine. Three consecutive groups will be run with approximately 8-10 participants in each group over the next year.",[224,225,226,227],"Race-related Stress","Depression, Anxiety","Quality of Life","Stress Reaction",[229,230,111,231,232,233,234],"Black","African American","Acceptance and Commitment Therapy","race-related stress","racial trauma","coping","2026-04-30",{"date":237,"type":37},"2026-05-06",{"date":239,"type":37},"2025-04-01",{"date":241,"type":21},"2029-06-30",{"name":43,"class":44},{"id":244,"slug":245,"hasResults":12,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":101,"sex":16,"minAge":102,"maxAge":157,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":254,"conditions":255,"keywords":257,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":264,"leadSponsor":266,"locationsCount":45},"100583782","bridge-the-gap-btg---black-youth-group-100583782","NCT06880809","Bridge the Gap (BTG) - Black Youth Group","Bridging the Gap: A Collaborative Intervention Group for Black Youth at Risk for Suicide","Bridge the Gap","Inclusion Criteria:\n\n* 12-17 years old\n* Identify as Black or African American or being of African descent\n* Have current suicidal ideation or suicidal ideation within the last 30 days\n* Have assent from the adolescent participant and consent from an individual's caregiver or guardian to participate.\n\nExclusion Criteria:\n\n* An active psychotic disorder or current psychosis symptoms\n* No history of suicide attempt(s) or suicide ideation in the past 30 days\n* Cognitive deficits or a medical condition diagnosed from a medical provider that precludes full understanding of study materials as assessed through an inability to complete the pre-treatment CAMS SSF \\& SSP\n* Caregivers, guardians, and\u002For the patient refuse to participate.",{"count":252,"type":21},16,[24],"The goal of this clinical trial is to develop and preliminarily test a culturally adapted suicide intervention specifically for black youth. The main question it aims to answer:\n\n-To evaluate the feasibility and acceptability of the group, as well as the preliminary efficacy of the group for decreasing suicidal thoughts and behaviors and increasing protective factors such as hope, positive ethnic identity, and family and peer support.\n\nParticipants will be asked to attend 10-week group intervention and complete pre-treatment and post-treatment assessment measures.",[256],"Suicide Prevention",[256,258,259,260],"Black Youth","Collaborative Assessment & Management of Suicidality (CAMS)","Group Intervention","2026-04-27",{"date":235,"type":37},{"date":180,"type":37},{"date":265,"type":21},"2027-06-01",{"name":43,"class":44},{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":101,"sex":16,"minAge":274,"maxAge":103,"enrollmentInfo":275,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":45},"100531096","individual-cerebral-hemodynamic-oxygenation-relationships-ichor-1-100531096","NCT06195345","Individual Cerebral Hemodynamic Oxygenation Relationships (ICHOR 1)","ICHOR 1","Inclusion Criteria:\n\n* Individuals who are able to tolerate an MRI.\n* Are patients scheduled for a clinically indicated MRI.\n* Between birth and up to 18 years.\n\nExclusion Criteria:\n\n* Presence of an MRI-incompatible device or implant (e.g. pacemakers, stents)\n* Unable to tolerate the enclosed spaces and loud noises for the duration of time in scanner required to obtain an MRI.\n* Preterm infants less than 25 weeks\n* Any patient who is clinically too unstable to extend their MRI by up-to 7.5 minutes.","1 Minute",{"count":276,"type":21},1000,"This is an observational study in patients who require clinical anesthesia. The main purpose of this study is to understand whether there are differences in the cerebral blood flow, and oxygen metabolism affected by different types of anesthesia. Subjects who require clinical anesthesia for a clinical MRI and for whom the use of anesthetics for the exam are in clinical equipoise are asked to join the study. All eligible subjects will be asked to provide informed consent before participating in the study.",[279,280,281,282,283],"HIE","TBI (Traumatic Brain Injury)","TBI","Hemodynamic Instability","Hypoxic-Ischemic Encephalopathy","2026-04-24",{"date":286,"type":37},"2026-04-29",{"date":288,"type":37},"2018-11-01",{"date":290,"type":21},"2035-11-01",{"name":43,"class":44},{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":16,"minAge":298,"maxAge":103,"enrollmentInfo":299,"targetDuration":301,"studyType":81,"phases":4,"briefSummary":302,"conditions":303,"keywords":307,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":319},"100436120","retinoblastoma-patient-clinical-database-and-tissue-repository-100436120","NCT04959097","Retinoblastoma Patient Clinical Database and Tissue Repository","Inclusion Criteria:\n\n* All patients, age 0 days to 18 years, with a diagnosis unilateral or bilateral retinoblastoma (RB) seen at CHLA (Children's Hospital Los Angeles).\n\nExclusion Criteria:\n\n* Patients referred for second opinions only and not treated at CHLA for any reason.","0 Years",{"count":300,"type":21},800,"3 Years","Retinoblastoma (RB) is a primary eye cancer that forms in the back of the eye of infants and toddlers. Traditionally, RB is diagnosed without a biopsy; tumor can only be studied once an eye has been surgically removed.\n\nGiven this limitation, we use aqueous humor (AH), the clear fluid in the front of the eye to detect specific markers, or information, that comes from the tumor itself.",[304,305,306],"Retinoblastoma","Retinoblastoma Bilateral","Retinoblastoma Unilateral",[304,308,309,310],"RB","Ocular oncology","Aqueous humor","2026-04-17",{"date":313,"type":37},"2026-04-22",{"date":315,"type":37},"2017-01-01",{"date":317,"type":21},"2030-12-31",{"name":43,"class":44},9,{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":16,"minAge":327,"maxAge":103,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":330,"briefSummary":332,"conditions":333,"keywords":336,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":346,"locationsCount":45},"100547853","phase-2-maralixibat-in-patients-with-cystic-fibrosis-and-constipation-100547853","NCT06413368","Maralixibat in Patients With Cystic Fibrosis and Constipation","Maralixibat in Patients With Cystic Fibrosis and Constipation, A Within-Subjects Pilot Study","Inclusion Criteria\n\n* Ages 1 to 18 years.\n* Proven diagnosis of Cystic Fibrosis confirmed by genetic testing or sweat chloride testing.\n* Proven diagnosis of chronic constipation, defined as a Bristol Stool Scale (BSS) score \\\u003C3 while on a stable conventional constipation therapy regimen.\n* Stable conventional constipation medication regimen (no medication changes or dose adjustments) for at least 4 weeks prior to enrollment. Conventional therapy may include stool softeners, stimulant laxatives, or dietary interventions.\n\nExclusion Criteria\n\n* Uncontrolled fat-soluble vitamin deficiency (Vitamin A, D, E, or K).\n* Changes to conventional constipation medication regimen within 4 weeks prior to initiation of Maralixibat.\n* Adequately treated chronic constipation, defined as a Bristol Stool Scale (BSS) score \\>3 on the current regimen.\n* Known allergy or sensitivity to Maralixibat or any study-related ingredients.\n* Inability or unwillingness of the participant or legal guardian\u002Frepresentative to provide written informed consent.","1 Year",{"count":329,"type":21},20,[58,331],"PHASE3","Chronic constipation is common in children with cystic fibrosis (CF), likely due to impaired chloride channel function that reduces intestinal secretions. Standard osmotic laxatives often provide inadequate relief in this population.\n\nMaralixibat is an ileal bile acid transporter inhibitor (IBATi) that increases the amount of bile acids reaching the colon. Bile acids can enhance intestinal secretion, reduce transit time, and soften stool. This study will evaluate whether Maralixibat improves stool consistency in children with CF who experience constipation.\n\nWe will enroll 20 children with CF and constipation, defined as a Bristol Stool Scale score \\\u003C4 for at least one week while on a stable laxative regimen. Each participant will receive Maralixibat for two weeks in addition to their usual laxatives. Families will record stool consistency and ease of defecation before and during treatment.\n\nThe primary objective is to determine whether Maralixibat improves stool consistency to a Bristol Stool Scale score \\>4. The secondary objective is to assess changes in ease of defecation using standardized questionnaires.",[334,335],"Constipation Chronic Idiopathic","Cystic Fibrosis",[337,335,338,339],"Maralixibiat","Chronic Constipation","Bristol Stool","2026-04-16",{"date":342,"type":37},"2026-04-21",{"date":344,"type":37},"2025-04-09",{"date":70,"type":21},{"name":43,"class":44},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":16,"minAge":354,"maxAge":103,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":357,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":371},"100367724","clinical-decision-support-tool-in-pards-pilot-study-100367724","NCT04068012","Clinical Decision Support Tool in PARDS Pilot Study","A Computerized Decision Support Tool for Ventilator Management in Pediatric Acute Respiratory Distress Syndrome Pilot Study","Inclusion Criteria:\n\n* Children \\> 1 month of age and \\>44 weeks gestation and ≤ 18 years of age AND\n* Supported on mechanical ventilation with pulmonary parenchymal disease (i.e. Pediatric Acute Respiratory Distress Syndrome (PARDS)) with Oxygen Saturation Index (OSI) ≥ 5) or Oxygenation Index (OI) ≥ 4 AND\n* Who are within 72 hours of initiation of invasive mechanical ventilation AND\n* Who are anticipated to require \\>72 hours mechanical ventilation.\n\nExclusion Criteria:\n\n* Conditions on enrollment that preclude conventional methods of weaning (i.e., status asthmaticus, severe lower airway obstruction, bronchiolitis, critical airway, Extra Corporeal Life Support (ECLS), intubation for Upper Airway Obstruction, Do Not Resuscitate orders, severe chronic respiratory failure, spinal cord injury above lumbar region, cyanotic heart disease (unrepaired or palliated)) OR\n* Conditions precluding the use of permissive hypercapnia or hypoxemia (i.e. intracranial hypertension, severe pulmonary hypertension)\n* Primary Attending physician refuses to enroll the patient","1 Month",{"count":356,"type":21},180,[24],"Previous clinical trials in adults with acute respiratory distress syndrome (ARDS) have demonstrated that ventilator management choices can improve Intensive Care Unit (ICU) mortality and shorten time on mechanical ventilation. This study seeks to scale an established Clinical Decision Support (CDS) tool to facilitate dissemination and implementation of evidence-based research in mechanical ventilation of infants and children with pediatric ARDS (PARDS).\n\nThis will be accomplished by using CDS tools developed and deployed in Children's Hospital Los Angeles (CHLA) which are based on the best available pediatric evidence, and are currently being used in an NHLBI funded single center randomized controlled trial (NCT03266016, PI: Khemani). Without CDS, there is significant variability in ventilator management of PARDS patients both between and within Pediatric ICUs (PICUs), but clinicians are willing to accept CDS recommendations. The CDS tool will be deployed in multiple PICUs, targeting enrollment of up to 180 children with PARDS. Study hypotheses:\n\n1. The CDS tool in will be implementable in nearly all participating sites\n2. There will be \\> 80% compliance with CDS recommendations and\n3. The investigators can implement automatic data capture and entry in many of the ICUs\n\nOnce feasibility of this CDS tool is demonstrated, a multi-center validation study will be designed, which seeks to determine whether the CDS can result in a significant reduction in length of mechanical ventilation (LMV).",[360,361,362],"Ventilation Therapy; Complications","Ventilator-Induced Lung Injury","Ards","2026-04-09",{"date":365,"type":37},"2026-04-14",{"date":367,"type":37},"2020-12-01",{"date":369,"type":21},"2027-07-01",{"name":43,"class":44},8,{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":101,"sex":16,"minAge":103,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":22,"phases":381,"briefSummary":382,"conditions":383,"keywords":385,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":45},"100632034","crisis-interventions-for-pediatric-providers---autism-version-100632034","NCT07508436","Crisis Interventions for Pediatric Providers - Autism Version","Safety Planning for Autistic Youth: A Randomized Controlled Trial With Providers in Pediatric Clinics","Inclusion Criteria:\n\n* Pediatric healthcare providers serving autistic youth in a DBP clinic in the U.S.\n* Willing and able to participate in the study and its activities, including remote training in either SPI or CIPP-A (depending on randomization)\n* Willing and able to provide informed consent\n* Comfortable speaking or communicating in English\n\nExclusion Criteria:\n\n* Pediatric healthcare providers not serving autistic youth\n* Pediatric healthcare providers not practicing in a DBP clinic in the U.S.\n* Unwilling and unable to participate in the study and its activities\n* Unwilling and unable to provide informed consent\n* Not comfortable speaking or communicating in English",{"count":380,"type":21},70,[24],"The goal of this clinical trial is to examine the initial feasibility, acceptability, and effectiveness of Crisis Interventions for Pediatric Providers - Autism version (CIPP-A) for providers serving autistic youth in outpatient settings. The main question aims to answer:\n\n* Assess whether CIPP-A is feasible and acceptable to providers in development behavioral pediatric clinics?\n* Assess whether CIPP-A shows initial effectiveness in increasing providers confidence in managing suicide risk in autistic youth?\n\nIf there is a comparison group: Researchers will compare CIPP-A to general safety planning intervention (SPI) on feasibility, acceptability, and initial effectiveness.\n\nParticipants will be randomized to receive training in SPI or CIPP-A and complete online surveys and interviews over 6-months to measure feasibility, acceptability, and initial effectiveness.",[384,256],"Autism",[384,256,386,387],"Safety Planning Intervention","Pediatric Clinics","2026-04-08",{"date":390,"type":37},"2026-04-13",{"date":392,"type":21},"2026-12-01",{"date":394,"type":21},"2028-12-31",{"name":43,"class":44},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":16,"minAge":102,"maxAge":103,"enrollmentInfo":402,"targetDuration":4,"studyType":22,"phases":404,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":45},"100587920","phase-3-early-re-initiation-of-semaglutide-post-sleeve-gastrectomy-in-youth-100587920","NCT06934655","Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth","Inclusion Criteria:\n\n* ages 12 to 18 years\n* Tanner stage 3 or higher\n* severe obesity (defined as a BMI greater than 35 kg\u002Fm2 or BMI ≥140% of the 95th percentile)\n* currently undergoing primary surgical weight loss through the pediatric bariatric surgery pathway at Children's Hospital Los Angeles\n* be willing to have blood collected before and after surgical procedure at defined points\n* be willing to have clinical data entered into a prospective database; 8) presence of a consenting caregiver\n* be taking semaglutide 2.4 mg weekly as part of their routine medical care prior to surgery as part of their obesity treatment program, apart from any planned surgical procedure.\n\nExclusion Criteria:\n\n* have a previous diagnosis of type 1 diabetes\n* taking any medications known to influence body composition or prevent weight loss or promote weight gain (e.g. prednisone)\n* have been diagnosed with syndromes or diseases that may influence the postoperative course (e.g., Cushing syndrome, Down syndrome, Prader Willi Syndrome)\n* have significant comorbid medical conditions necessitating frequent hospitalization that may require interruption of medications and\u002For that would make early re-initiation of semaglutide unsafe due to the other medical comorbidities\n* refuse to comply with eligibility criteria.",{"count":403,"type":21},150,[331],"This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants will be randomized to either (1) semaglutide 2.4 mg weekly or (2) standard care for 24 months. Primary, secondary, and tertiary outcomes will be assessed at multiple time points: 1-month, day of surgery, and 1-, 3-, 6-, 9-, 12-, 18-, and 24-months postoperatively. We hypothesize that early re-initiation of semaglutide will be safe, well-tolerated, and lead to greater improvements in obesity, cardiometabolic risk, and eating behaviors.",[407,408,409],"Pediatric Obesity","Metabolic and Bariatric Surgery","Semaglutide","2026-03-16",{"date":412,"type":37},"2026-03-17",{"date":414,"type":21},"2026-06-01",{"date":416,"type":21},"2033-11-01",{"name":43,"class":44},{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":16,"minAge":424,"maxAge":4,"enrollmentInfo":425,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":427,"conditions":428,"keywords":431,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":45},"100625840","virtual-reality-vr-for-interventional-radiology-ir-procedures-100625840","NCT07427862","Virtual Reality (VR) for Interventional Radiology (IR) Procedures","Inclusion Criteria:\n\n* Children who are at least 8 years old\n* Children who are English speaking with caregivers who are English speaking or Spanish speaking.\n* Children who are undergoing an interventional radiology procedure are eligible to participate in this project.\n* Only children who are in the normal range of development will be recruited for this study. This will be assessed by report from the parents. The rationale for excluding patients with developmental delay is that due to their cognitive impairments, such children react to the stressors of surgery differently than do children without such developmental delay. It is unclear how such children would use the interventions included in this study, and it is likely that their responses on baseline and outcome measures will differ from children of normal developmental parameters.\n\nExclusion Criteria:\n\n* Children who are currently taking pain medication or anxiolytic medication will be excluded from this study.\n* Children with a psychiatric disorder, organic brain syndrome, intellectual disability, or other known cognitive\u002Fneurological disorders\n* Children with visual, auditory, or tactile deficits that would interfere with the ability to complete the experimental tasks\n* Children with a history of seizure disorder.\n* Children currently sick with flu-like symptoms or experiencing a headache or earache.\n* Children with known or suspected motion sickness.\n* Children with cochlear implants or pacemakers.","8 Years",{"count":426,"type":21},500,"The goal of this clinical trial is to to utilize Virtual Reality during their interventional radiology procedure to help reduce any pain and anxiety experienced during the procedure in patients above the age of 8 undergoing interventional radiology procedures. The main questions it aims to answer are:\n\n* To determine if Virtual Reality is more effective than standard care for reducing pain and anxiety in children undergoing painful interventional radiology procedures. It is hypothesized that children in the Virtual Reality condition will experience reduced pain and anxiety compared to children receiving standard of care.\n* To evaluate caregiver's assessment of patient distress and their satisfaction with Virtual Reality compared to standard of care. It is hypothesized that caregiver satisfaction with the medical procedure will be significantly greater in the Virtual Reality group compared to the standard of care group. It is hypothesized that caregivers will perceive lower pain\u002Fanxiety when their child receives Virtual Reality compared to standard of care.\n\nParticipants will complete pre and post surveys before and after interventional radiology procedures. Participants will use Virtual Reality headsets while undergoing procedure.",[429,430],"Pain","Procedural Anxiety",[432,433,430,429,434],"Virtual reality","Interventional radiology","Pediatrics","2026-03-05",{"date":437,"type":37},"2026-03-09",{"date":439,"type":21},"2026-03-01",{"date":441,"type":21},"2026-09-01",{"name":43,"class":44},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":16,"minAge":424,"maxAge":54,"enrollmentInfo":450,"targetDuration":4,"studyType":22,"phases":452,"briefSummary":453,"conditions":454,"keywords":456,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":45},"100555788","type-2-continuous-glucose-monitoring-academy-100555788","NCT06516640","Type 2 Continuous Glucose Monitoring Academy","Randomized Control Trial Evaluating the Impact of Continuous Glucose Monitoring Academy Education Curriculum Versus Standard Care on Glycemic Outcomes for Youth With Type 2 Diabetes","Inclusion Criteria:\n\n1. Current age of 8-21 years;\n2. T2D diagnosis;\n3. Able to speak, read, and write English or Spanish\n\nExclusion Criteria:\n\na. Known history of medical adhesive allergies;",{"count":451,"type":21},60,[24],"The goal of this clinical trial is to evaluate the Impact of Continuous Glucose Monitoring Academy Education Curriculum Versus Standard Care on Glycemic Outcomes for Youth With Type 2 Diabetes (T2D):\n\n* The first aim is to determine how feasible it is to adapt the Continuous Glucose Monitoring Academy curriculum to teach youth with T2D glucose management strategies.\n* The second aim is to evaluate the effects of the Continuous Glucose Monitoring Academy metrics.\n* The third aim is to explore the relationships between these metrics with diabetes distress, diabetes family responsibilities, and process metrics.\n\nParticipants will join for a total of four weeks of education, followed by a six-month clinical review. They will have access to an online workbook and videos, and will participate in virtual sessions with a diabetes educator who will cover glucose management strategies in-depth. Participants will wear their preferred Continuous Glucose Monitoring system (Dexcom or FreeStyle Libre) provided via insurance and inserted at the baseline visit.",[455],"Type 2 Diabetes",[457,458,459,455],"Continuous Glucose Monitoring","Glycemic Control","Diabetes Education","2026-02-04",{"date":462,"type":37},"2026-02-06",{"date":464,"type":37},"2025-06-23",{"date":466,"type":21},"2026-12-30",{"name":43,"class":44},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":16,"minAge":424,"maxAge":103,"enrollmentInfo":475,"targetDuration":4,"studyType":22,"phases":477,"briefSummary":478,"conditions":479,"keywords":481,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":486,"locationsCount":45},"100547456","cgm-academy-for-youth-with-type-1-diabetes-100547456","NCT06408207","CGM Academy for Youth With Type 1 Diabetes","Randomized Control Trial Evaluating the Impact of CGM Academy Education Curriculum Versus Standard Care on Glycemic Outcomes for Youth With Type 1 Diabetes","Inclusion Criteria:\n\n* Current age of 8-18 years, age group eligible for CGM therapy with Dexcom G6 and G7\n* T1D duration ≥6 months, as insulin adjustments during honeymoon stage differs from establishedT1D\n* Able to speak, read, and write English or Spanish\n* Smartphone compatible with Dexcom G6 and G7application\n* Ability to participate in virtual visits\n\nExclusion Criteria:\n\n• Known history of medical adhesive allergies",{"count":476,"type":21},90,[24],"The goal of this randomized clinical trial is to compare the effects of a virtual education curriculum in blood glucose variation of youth with type 1 diabetes wearing continuous glucose monitoring (CGM) device. The main questions the study aims to answer are:\n\n* Do participants undertaking the proposed curriculum present improved glucose variation than participants of standard education?\n* Explore relationships between participant's glycemic outcomes with diabetes distress, diabetes family responsibilities, and number of hours of diabetes education.\n\nParticipants in the intervention group will:\n\n* receive an interactive workbook with problem-based learning scenarios and video links about CGM and glucose management strategies.\n* participate in four in-depth online group sessions with diabetes care and education specialists\n* complete questionnaires three times: at the time of study enrollment, week 4 and 6 months.\n\nParticipants in the comparison group will:\n\n* receive standard education provided to all patients at CHLA\n* complete questionnaires three times: at the time of study enrollment, week 4 and 6 months.",[480],"Type1 Diabetes",[457,458,459,480],{"date":462,"type":37},{"date":484,"type":37},"2025-05-01",{"date":466,"type":21},{"name":43,"class":44},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":101,"sex":16,"minAge":493,"maxAge":494,"enrollmentInfo":495,"targetDuration":4,"studyType":22,"phases":497,"briefSummary":498,"conditions":499,"keywords":501,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":45},"100556527","very-brief-exposure-development-of-a-novel-exposure-modality-for-social-anxiety-disorder-in-transition-age-youth-100556527","NCT06526260","Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth","Inclusion Criteria:\n\n* Patient Population\n\n  * Males and females aged 16-22. This age range corresponds with our prior studies of very brief exposure (VBE) in Specific Phobia and will include older adolescents while minimizing potential developmental effects on circuit activation.\n  * Youth with a Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of Social Anxiety Disorder (SAD) on Kiddie Schedule for Affective Disorders and Schizophrenia for School-Aged Children, Computerized version (K-SADS-COMP) for youth ages 16-17, or the computerized version of Structured Clinical Interview for the DSM-5 (NetSCID) for youth ages 18+.\n* Healthy Population\n\n  • Male and female youth aged 16-22.\n* Parents • Parent\u002Fcaregiver of all ages, no restrictions who are fluent in either English or Spanish.\n\nExclusion Criteria:\n\n* Patient Population\n\n  * Primary language other than English or Spanish.\n  * Active suicidality on the Colombia-Suicide Severity Scale (plan, intent, or behavior)\n  * Ferromagnetic implants (e.g., pacemaker), metal braces, retainers, tattoos or permanent make-up with metallic content, transdermal medicinal patches that cannot be removed.\n  * Current psychoactive medication.\n  * Lifetime diagnosis of: obsessive-compulsive disorder (OCD), psychotic, bipolar, autism spectrum disorder, intellectual disability on the KSADS-COMP or NetSCID.\n  * Any serious neurological or medical conditions (e.g., Lupus, cancer, human immunodeficiency virus positive (HIV+)) as reported by potential participants.\n  * Current Post-Traumatic Stress Disorder (PTSD) diagnosis.\n  * Current severe substance abuse (except tobacco\u002Fnicotine).\n  * Pregnancy, as determined by the participant's self-report prior to the magnetic resonance imaging (MRI) scan.\n* Healthy Population\n\n  * Primary language other than English or Spanish.\n  * Lifetime disorders: any anxiety disorders, OCD, psychotic, bipolar, autism spectrum disorder, intellectual disability; any psychiatric disorder in the past 2 years\n  * Current depression disorder.\n  * Active psychiatric disorder in the past 2 years.\n  * Serious neurological or medical conditions.\n  * Current psychoactive medication.\n  * Ferromagnetic implants (e.g., pacemaker), metal braces, retainers, tattoos or permanent make-up with metallic content, transdermal medicinal patches that cannot be removed.\n  * Active suicidality on the Colombia-Suicide Severity Scale (plan, intent, or behavior).\n  * Pregnancy, as determined by the participant's self-report prior to the MRI scan.\n* Parents • Primary language other than English or Spanish.","16 Years","22 Years",{"count":496,"type":21},80,[24],"The goal of this clinical trial is to identify the circuit activations by very brief exposure (VBE) among youth with social anxiety disorder (SAD) in order to develop a novel intervention for those with SAD. The secondary objectives of this study are to measure the effect of VBE on subjective fear ratings, and participants' awareness and tolerance of the exposure stimuli.\n\n* The primary outcome of this study is the mean activation of frontostriatal and prefrontal brain regions to facial stimuli, as measured by Blood Oxygen Level Dependent (BOLD) response, in 4 regions of interest during the magnetic resonance imaging (MRI).\n* Another primary outcome of the study is to identify networks of regions subserving emotion regulation and attention, as measured by BOLD response of corresponding brain regions.\n\nSecondary Outcomes\n\n-The secondary outcome of this study is the fear induced by exposure to facial expression stimuli as measured by a 4-point fear scale during the functional magnetic resonance imaging (fMRI) after each block of 10 facial expression stimuli trials.\n\nParticipants will participate in an interview where they will answer questions both inside and outside of the MRI scan. Participants will be asked to rate on a scale the imagines they see while undergoing MRI scan.",[500],"Social Anxiety Disorder",[502,503],"Youth","Very Brief Exposure","2025-12-11",{"date":506,"type":37},"2025-12-16",{"date":508,"type":37},"2024-08-14",{"date":510,"type":21},"2026-07",{"name":43,"class":44},{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":101,"sex":16,"minAge":103,"maxAge":519,"enrollmentInfo":520,"targetDuration":4,"studyType":22,"phases":521,"briefSummary":522,"conditions":523,"keywords":525,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":45},"100532866","the-effects-of-very-brief-exposure-on-ptsd-in-us-combat-veterans-100532866","NCT06218381","The Effects of Very Brief Exposure on PTSD in U.S. Combat Veterans","PTSD","Inclusion Criteria:\n\nPatient Population\n\n* Males and females ages 18-50\n* Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) diagnosis of PTSD\n* Traumatic event is a combat-based experience (e.g., being injured, watching a buddy be killed)\n* Minimum score of 18 on the Combat Experience Scale (CES)\n* Minimum score of 3 or more on Primary Care (PC)-PTSD-5\n* Participants with other cooccurring psychiatric disorders (e.g., anxiety, ADHD) will be included to ensure a representative sample.\n\nHealthy Population\n\n• Males and Females, ages 18-50\n\nExclusion Criteria:\n\nPatient Population\n\n* Treatment for PTSD, substance abuse, or mental health concerns in the past 6 months\n* 10 or more years since the combat trauma\n* Acute intoxication\n* Severe level of Substance Dependence (6 or more DSM-V symptoms)\n* Prior diagnosis of Autistic Spectrum Disorders\n* Current or past psychotic disorders or active psychotic symptoms\n* Current Bipolar I Disorder\n* Dementia\n* Neurological or serious medical conditions (e.g., stroke, epilepsy\u002F seizure disorder, cancer, Lupus, HIV+);\n* Traumatic brain injury\n\nHealthy Population\n\n* Ferromagnetic implants (e.g., pacemaker), metal braces, retainers, tattoos or permanent make up w\u002F metallic content, transdermal medicinal patches that cannot be removed\n* Neurological or serious medical conditions (e.g., stroke, epilepsy\u002F seizure disorder, cancer, Lupus, HIV+);\n* Lifetime Diagnosis of PTSD, Tourette's Syndrome, Bipolar Disorder, Substance Dependence, Eating Disorder, Autism Spectrum Disorder, a psychotic disorder, Acute Stress Disorder\n* Lifetime history of traumatic event defined as a life-threatening event involving physical attack, guns, fire or explosion (i.e the kinds of traumatic events combat veterans are likely to experience)\n* Traumatic Brain Injury\n* Birth at less than 37 weeks gestational age\n* Claustrophobia\n* Anxiety Disorder, Mood Disorder, Substance Abuse Disorder, Adjustment Disorder in past 2 years\n* Treatment for mental health concern in past 2 years\n* Pregnant Females","50 Years",{"count":496,"type":21},[24],"The goal of this clinical trial is to develop a new behavioral treatment for U.S. combat veterans with post-traumatic stress disorder (PTSD), very brief exposure to combat-related stimuli. The main questions it aims to answer are:\n\n1. How does Very Brief Exposure (combat images and control everyday images) and Visible Exposure to combat stimuli affect brain activity and subjective fear ratings?\n2. To what extent are participants aware of the stimuli presented and tolerating the exposures?\n\nAll participants will view both very brief exposure and visible exposure to combat stimuli in the functional magnetic brain imaging (fMRI) scan. They will provide ratings of fear, awareness, and tolerability. Researchers will compare U.S. combat veterans with PTSD and healthy controls to confirm differences in brain region activation and ratings.",[524],"Post Traumatic Stress Disorder",[524,526,503],"Veteran",{"date":528,"type":37},"2025-12-18",{"date":530,"type":37},"2024-03-22",{"date":532,"type":21},"2027-07",{"name":43,"class":44},{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":540,"eligibilityCriteria":541,"healthyVolunteers":101,"sex":16,"minAge":542,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":22,"phases":545,"briefSummary":546,"conditions":547,"keywords":551,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":45},"100522614","self-concept-reinforcement-for-early-school-readiness-100522614","NCT06084910","Self-Concept Reinforcement for Early School Readiness","Self-Concept Reinforcement for Early School Readiness: Pilot Randomized Controlled Trial of a Clinic-Based Intervention for Young African American Children","SCR4ESR","Inclusion Criteria:\n\n* Parent\u002FLegal guardian must be 18 years old or older\n* Speak English\n* Legal guardian of the index 2 to 4-year-old African American child\n\nExclusion Criteria:\n\n* Index child has severe cognitive impairment or communication difficulties (i.e., severe intellectual disability or nonverbal)\n* Plan to move outside of the Children's Hospital Los Angeles (CHLA) service area in the next 15 months\n* CHLA employee\n* Participated in Aim 1 interviews","2 Years",{"count":544,"type":21},134,[24],"The goal of this pilot randomized controlled trial is to evaluate a self-concept intervention (Self-Concept Reinforcement for Early School Readiness (SCR4ESR)) in young African American children using experimental and mixed methods. SCR4ESR provides self-concept themed children's books and advice at health supervision visits of children enrolled at ages 2-4 years.\n\nThe specific aims of the proposed project are to:\n\n1. assess the feasibility and acceptability of SCR4ESR implementation among parents and providers,\n2. evaluate the capacity of SCR4ESR to improve self-concept reinforcement and book-sharing behaviors in parents of young African American children, and 3) evaluate the capacity of SCR4ESR to improve behavioral health and literacy in young African American children. The interviews conducted in Aim 1 will guide refinement of the intervention tested in Aims 2 and 3.\n\nThe qualitative assessment will be complemented by quantitative trial statistics (e.g., recruitment rate) that inform trial feasibility and acceptability. Finally, the mechanism by which SCR4ESR impacts the primary outcome, behavioral health, and the secondary outcome, literacy, will be evaluated by structural equation modeling. This project will inform the development and implementation of early childhood interventions that improve the health of African Americans.",[548,549,550],"Child Behavior","Child Behavior Problem","Child Behavior Disorders",[548,552,553,554,555],"Literacy","Early Childhood","Parenting","Self-Concept",{"date":506,"type":37},{"date":558,"type":37},"2024-07-03",{"date":560,"type":21},"2028-11-30",{"name":43,"class":44},{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":16,"minAge":102,"maxAge":103,"enrollmentInfo":569,"targetDuration":4,"studyType":22,"phases":571,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":580,"locationsCount":122},"100587027","implementation-of-team-clinic-for-type-2-diabetes-tct2-100587027","NCT06923046","Implementation of Team Clinic for Type 2 Diabetes (TCT2)","Implementation of Team Clinic for Type 2 Diabetes (TCT2): A Randomized Standard Care-controlled Two-site 80-subject Clinical Trial of Shared Medical Appointment Model for Adolescents With Type 2 Diabetes","Patient\u002FAYA Participants\n\nInclusion Criteria:\n\n* Receives care for type 2 diabetes at either CHLA or UCSF\n* English speaking youth\n* Youth prescribed medication for type 2 diabetes\n* English or Spanish speaking caregivers\n* Age 12 to 18 years old at the time of enrollment\n* Willingness to attend clinic visits and participate in group session (if randomized to Team Clinic), complete surveys\n\nExclusion Criteria:\n\n* Participants who are non-verbal or unable to participate in group activities and discussions\n* Pregnancy\n* Inability or unwillingness of individual or legal guardian\u002Frepresentative to give written informed assent\u002Fconsent\n\nCaregiver\u002FParents Participants\n\nInclusion Criteria:\n\n* Has a child between the ages of 12 and up to 18 at the time of enrollment who receives care for T2D in the endocrinology clinic at CHLA. The child must provide consent\u002Fassent to participate as a youth participant.\n* Speaks English of Spanish. Over 95% of our T2D population speaks one of those two languages. Our facilitator will be bilingual in English and Spanish. It is not feasible for the facilitator to also speak another language. Having a language interpreter for discussion groups will affect the dynamics and flow of the group session\n* Willingness to participate in group session (if their child is randomized to Team Clinic) and complete surveys.\n\nExclusion Criteria:\n\n-Inability or unwillingness of individual to give written informed consent",{"count":570,"type":21},160,[24],"The goal of this clinical trial is to learn if shared medical appointment is an acceptable way to deliver care to youth with type 2 diabetes.\n\nThe main question\\[s\\] it aims to answer are:\n\n* Is shared medical appointments an acceptable care delivery model for this population?\n* Does shared medical appointment improve psychosocial outcomes for this population?\n\nParticipants will attend quarterly clinic appointments and group activities and take surveys. Researchers will compare this intervention to standard of care.",[455],"2025-10-27",{"date":576,"type":37},"2025-10-29",{"date":578,"type":37},"2025-08-14",{"date":70,"type":21},{"name":43,"class":44},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":16,"minAge":298,"maxAge":4,"enrollmentInfo":587,"targetDuration":4,"studyType":22,"phases":589,"briefSummary":590,"conditions":591,"keywords":593,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":605,"locationsCount":45},"100594739","parent-navigator-program-pnp-to-improve-outcomes-in-latinox-children-and-parents-100594739","NCT07023367","Parent Navigator Program (PNP) to Improve Outcomes in Latino\u002Fx Children and Parents","Latino\u002Fx Infants:\n\nInclusion Criteria:\n\n* Infants born with CHD requiring medical\u002Fsurgical intervention at less than 30 days of age\n* Identify as Latino\u002Fx\n\nExclusion Criteria:\n\n* Presence of a major genetic syndrome\n* Intraventricular hemorrhage or other major structural brain lesion\n* Undergoing end of life care\n\nParents of Latino\u002Fx Infants:\n\nInclusion Criteria:\n\n* Identify as Latino\u002Fx\n\nExclusion Criteria:\n\n* Not fluent in English or Spanish",{"count":588,"type":21},40,[24],"The goal of this clinical trial is to see if a Parent Navigator Program (PNP) is helpful for Latino\u002Fx parents of babies with congenital heart disease (CHD) to get connected to developmental follow-up services. The main question it aims to answer are:\n\n* Do families assigned to the Parent Navigator Program (PNP) have higher rates of connection to High-Risk Infant Follow-Up (HRIF)\u002FEarly Intervention (EI) compared to the standard care group 6 months after randomization?\n* Do children assigned to the Parent Navigator Program (PNP) have better neurodevelopmental outcomes (NDOs) compared to the standard care group 6 months after randomization?\n* Do parents assigned to the Parent Navigator Program (PNP) have decreased parental stress compared to the standard care group?\n\nResearchers will compare the Parent Navigator group to the standard care group to see if parent navigator group is helpful in connecting families to High-Risk Infant Follow-Up (HRIF)\u002FEarly Intervention (EI), improving neurodevelopmental outcomes (NDOs), and lowering parental stress.\n\nParticipants will:\n\n* Undergo developmental assessments and survey at newborn stage and at 6 months\n* Participants randomly assigned to the Parent Navigator group will have weekly (at least) phone calls with the parent navigator\n* Participants randomly assigned to the Parent Navigator group will complete a 30-minute phone interview about their experience with the parent navigator program 6 months after random assignment",[592],"Congenital Heart Disease",[592,594,595,596,597,598],"Parent Navigator Program","Latino\u002Fx Children","High-Risk Infant Follow-up (HRIF)","Early Intervention (EI)","Neurodevelopmental Outcomes","2025-09-08",{"date":601,"type":37},"2025-09-12",{"date":603,"type":21},"2025-10-01",{"date":182,"type":21},{"name":43,"class":44},{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":4,"eligibilityCriteria":612,"healthyVolunteers":101,"sex":16,"minAge":301,"maxAge":4,"enrollmentInfo":613,"targetDuration":4,"studyType":22,"phases":615,"briefSummary":616,"conditions":617,"keywords":619,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":634,"locationsCount":45},"100543811","effects-of-using-a-storybook-to-explain-leukemia-to-children-versus-the-standard-child-life-intervention-on-parental-stress-100543811","NCT06360718","Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.","Effects of a Storybook About New Leukemia Diagnosis Versus Standard Child Life Intervention on Parental Stress: a Pilot Randomized Controlled Study","Parents are approached and enrolled on the inpatient Hematology Oncology unit at CHLA, during the admission where their child received a new leukemia diagnosis.\n\nInclusion Criteria:\n\n* Parent\u002FLegal Guardian of a child a. who is school-aged (3-16 years old) with a new leukemia diagnosis b. with a new leukemia diagnosis who is not school-aged but is a sibling of a school-aged child (\\\u003C3 years or \\>16 years old).\n* Parent\u002Flegal guardian is able to speak, read, and write English or Spanish, and give informed consent 3. Parent\u002Flegal guardian is over 18 years of age.\n\nExclusion Criteria:\n\n* Their school-aged children have developmental or cognitive delays, and\u002For other chronic illnesses.\n* Their school-aged child does not give assent to participate.",{"count":614,"type":21},140,[24],"The goal of this clinical trial is to measure the effects of using a storybook versus standard child life intervention with parents of children newly diagnosed with leukemia on parental stress.\n\nThe main questions it aims to answer are:\n\n* What effect will the storybook have on parent\u002Flegal guardian stress at three timepoints: baseline, discharge, and follow up?\n* Will this storybook impact parent\u002Flegal guardian comfort levels and improve their child's understanding?\n\nParticipants will be asked to complete surveys at three timepoints, prior to and following child life intervention and about 3.5 months later. During child life interventions, participants will receive resources and support to explain leukemia to their school aged, 3-16-year-old, child (patient or sibling).\n\nResearchers will compare Intervention and Control Groups to see if parental stress is lower in those who received the storybook in addition to the standard child life intervention versus the standard child life intervention alone.",[618],"Leukemia",[620,621,618,622,623,624,625,626,200,627],"Parental stress","Diagnosis education","Child life","Cancer","Chemotherapy","Hair Loss","School-Age","Family-Centered Care","2025-07-30",{"date":630,"type":37},"2025-08-03",{"date":632,"type":37},"2024-02-03",{"date":39,"type":21},{"name":43,"class":44},{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":639,"acronym":640,"eligibilityCriteria":641,"healthyVolunteers":101,"sex":16,"minAge":4,"maxAge":53,"enrollmentInfo":642,"targetDuration":4,"studyType":22,"phases":644,"briefSummary":646,"conditions":647,"keywords":650,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":661,"locationsCount":45},"100600909","phase-4-individual-cerebral-hemodynamic-oxygenation-relationships---ichor-4-100600909","NCT07103616","Individual Cerebral Hemodynamic Oxygenation Relationships - ICHOR 4","ICHOR","Inclusion Criteria:\n\n* Patients who are scheduled for a clinically indicated MRI at the sponsor institution.\n* Patients who are able to tolerate an MRI.\n* Patients who require clinical anesthesia for their MRI.\n* Patients with conditions not believed to alter oxygen metabolism or blood flow in the brain, including but not limited to patients with orthopedic indications, undescended testicles, hernia repairs, term equivalent age scans.\n* Patients who have no medical conditions that make the use of propofol or dexmedetomidine better for their clinical outcome.\n* Patients between birth and up-to 7 year of age.\n* Patients with conditions known to alter oxygen metabolism or blood flow in the brain, e.g. traumatic brain injury, hypoxic ischemic encephalopathy, tumor.\n\nExclusion Criteria:\n\n* Patients with an MRI-incompatible device or implant (e.g. pacemakers, stents)\n* Preterm infants less than 25 weeks postmenstrual age (PMA) at the time of the scan.\n* Patients who are clinically too unstable to extend their MRI by up-to 10 minutes.\n* Patients who do not require clinical anesthesia.\n* Patients at risk for propofol infusion syndrome (known severe metabolic acidosis, hyperkalemia, lipemia, rhabdomyolysis, hepatomegaly, renal failure, ECG ST segment elevation, and\u002For cardiac failure)\n* Patient at risk for sensitivity to volatile halogenated anesthetic agents (known congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval),\n* Patients with Perioperative Hyperkalemia (known neuromuscular disease, particularly Duchenne muscular dystrophy)",{"count":643,"type":21},130,[645],"PHASE4","The goal of this clinical trial is to understand whether there are differences in the cerebral blood flow, and oxygen metabolism affected by two types of anesthesia: Propofol or Dexmedetomidine. Subjects who require clinical anesthesia for a clinical MRI and for whom the use of Propofol and Dexmedetomidine are in clinical equipoise will be offered to have the anesthesia they will receive during their MRI randomized.\n\n* Change in cerebral blood flow (ml blood\u002F100g\u002Fmin)\n* Change in cerebral metabolic rate of oxygen (ml O2\u002F100g\u002Fmin)\n\nResearchers will compare Propofol (Group A) to Dexmedetomidine (Group B) to see if compare the hemodynamic response to anesthesia.\n\nParticipants will be randomized to receive one of two equally safe anesthetics (Propofol or Dexmedetomidine).",[648,649],"Anesthesia; Reaction","Anesthesia",[651,652,653,649],"Magnetic Resonance Imaging","Cerebral Blood Flow","Cerebral Metabolism","2025-07-29",{"date":656,"type":37},"2025-08-05",{"date":658,"type":21},"2025-09-01",{"date":660,"type":21},"2028-09-01",{"name":43,"class":44},""]